Tags

Type your tag names separated by a space and hit enter

Oral propranolol for the treatment of periorbital infantile hemangioma: a preliminary report from oman.
Middle East Afr J Ophthalmol. 2011 Oct; 18(4):298-303.ME

Abstract

PURPOSE

To investigate the efficacy and safety of oral propranolol in the management of periorbital infantile hemangioma in four subjects.

MATERIALS AND METHODS

Consecutive patients who presented with periorbital capillary hemangioma with vision-threatening lesions were prospectively enrolled in this study between January 2009 and October 2010. All subjects underwent treatment with 2 mg/kg/day oral propranolol. All subjects underwent ocular, systemic, and radiologic evaluations before treatment and at periodic intervals after starting therapy. Side effects from therapy were also evaluated.

RESULTS

Four subjects, between 3 months and 19 months of age, with periorbital hemangioma were enrolled in this study. Two subjects had been previously treated with oral corticosteroids with unsatisfactory response. All subjects had severe ptosis, with the potential for deprivation amblyopia. Three subjects had orbital involvement. After hospital admission, oral propranolol was initiated in all subjects under monitoring by a pediatric cardiologist. Subsequent therapy was performed with periodic out-patient monitoring. All subjects had excellent response to treatment, with regression of periorbital and orbital hemangioma. There were no side effects from therapy.

CONCLUSIONS

Oral propranolol for periorbital hemangioma was effective in all the four subjects. Oral propranolol may be appropriate for patients who are nonresponsive to intralesional or systemic steroids. In patients with significant orbital involvement and lesions causing vision-threatening complications, oral propranolol can be the primary therapy.

Authors+Show Affiliations

Department of Ophthalmology, Sultan Qaboos University Hospital, Muscat, Oman.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22224018

Citation

Harikrishna, Beena, et al. "Oral Propranolol for the Treatment of Periorbital Infantile Hemangioma: a Preliminary Report From Oman." Middle East African Journal of Ophthalmology, vol. 18, no. 4, 2011, pp. 298-303.
Harikrishna B, Ganesh A, Al-Zuahibi S, et al. Oral propranolol for the treatment of periorbital infantile hemangioma: a preliminary report from oman. Middle East Afr J Ophthalmol. 2011;18(4):298-303.
Harikrishna, B., Ganesh, A., Al-Zuahibi, S., Al-Jabri, S., Al-Waily, A., Al-Riyami, A., Al-Azri, F., Masoud, F., & Al-Mujaini, A. (2011). Oral propranolol for the treatment of periorbital infantile hemangioma: a preliminary report from oman. Middle East African Journal of Ophthalmology, 18(4), 298-303. https://doi.org/10.4103/0974-9233.90131
Harikrishna B, et al. Oral Propranolol for the Treatment of Periorbital Infantile Hemangioma: a Preliminary Report From Oman. Middle East Afr J Ophthalmol. 2011;18(4):298-303. PubMed PMID: 22224018.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral propranolol for the treatment of periorbital infantile hemangioma: a preliminary report from oman. AU - Harikrishna,Beena, AU - Ganesh,Anuradha, AU - Al-Zuahibi,Sana, AU - Al-Jabri,Samia, AU - Al-Waily,Ahmed, AU - Al-Riyami,Adil, AU - Al-Azri,Faisal, AU - Masoud,Feraz, AU - Al-Mujaini,Abdullah, PY - 2012/1/7/entrez PY - 2012/1/10/pubmed PY - 2012/1/10/medline KW - Amblyopia KW - Infants KW - Orbital Hemangioma KW - Propranolol SP - 298 EP - 303 JF - Middle East African journal of ophthalmology JO - Middle East Afr J Ophthalmol VL - 18 IS - 4 N2 - PURPOSE: To investigate the efficacy and safety of oral propranolol in the management of periorbital infantile hemangioma in four subjects. MATERIALS AND METHODS: Consecutive patients who presented with periorbital capillary hemangioma with vision-threatening lesions were prospectively enrolled in this study between January 2009 and October 2010. All subjects underwent treatment with 2 mg/kg/day oral propranolol. All subjects underwent ocular, systemic, and radiologic evaluations before treatment and at periodic intervals after starting therapy. Side effects from therapy were also evaluated. RESULTS: Four subjects, between 3 months and 19 months of age, with periorbital hemangioma were enrolled in this study. Two subjects had been previously treated with oral corticosteroids with unsatisfactory response. All subjects had severe ptosis, with the potential for deprivation amblyopia. Three subjects had orbital involvement. After hospital admission, oral propranolol was initiated in all subjects under monitoring by a pediatric cardiologist. Subsequent therapy was performed with periodic out-patient monitoring. All subjects had excellent response to treatment, with regression of periorbital and orbital hemangioma. There were no side effects from therapy. CONCLUSIONS: Oral propranolol for periorbital hemangioma was effective in all the four subjects. Oral propranolol may be appropriate for patients who are nonresponsive to intralesional or systemic steroids. In patients with significant orbital involvement and lesions causing vision-threatening complications, oral propranolol can be the primary therapy. SN - 0975-1599 UR - https://www.unboundmedicine.com/medline/citation/22224018/Oral_propranolol_for_the_treatment_of_periorbital_infantile_hemangioma:_a_preliminary_report_from_oman_ L2 - http://www.meajo.org/article.asp?issn=0974-9233;year=2011;volume=18;issue=4;spage=298;epage=303;aulast=Harikrishna DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.